LATEST NEWS IN PROSTATE CANCER
Watch PCRI's New Prostate Cancer 101 Video Series
WANT TO LEARN THE BASICS
OF PROSTATE CANCER?
WE HAVE A PROSTATE CANCER 101
ANIMATED VIDEO SERIES ON OUR WEBSITE!
Check Out The Prostate Cancer 101 Video Series
We're pleased to announce that we'll be working with KMI on videos for the new SHADES program. Stay tuned for more information on this groundbreaking patient education series.
In the mean, time check out our Prostate Cancer 101 video series below:
Prostate Biopsy and Alternatives
It seems we have a national passion for prostate biopsies. A million men are biopsied every year. Two hundred thousand of them will be diagnosed with prostate cancer and about half of these with Low-Risk disease, a condition that can be safely monitored without immediate treatment. Even so, more than half of these men with Low-Risk will undergo prompt, radical treatment. Sadly, irrational fears rooted in the electrifying word “cancer” drive most men into taking immediate action.
New Approach To Prostate Cancer Screening
Why Screen for Prostate Cancer?
Screening finds earlier stage cancers, allows for simpler treatments with fewer side effects, and saves lives. For example, in 1985, prior to PSA screening, the prostate cancer five-year survival rate was 69% compared to 99% in 2006. It’s unclear whether this dramatic survival increase is entirely due to PSA screening. Other factors, such as improved therapy have also contributed.
Let’s Get Real About The Overtreatment of Prostate Cancer
Eight years ago, at the age of 55, I learned I had prostate cancer. At that time, ignoring three separate doctors’ recommendations, I decided to forego surgery. One of my doctors, a urologist, gave me the name of a patient who was on active surveillance. I contacted Brad Cole and our conversation gave me the courage to try it myself.
A New, Improved Ultrasensitive PSA Test: ProsVue
Bottom line: Previously published studies of standard ultrasensitive PSA assays used after surgery have shown some utility for predicting future cancer relapse. Therefore it is likely that ProsVue, which is substantially more accurate than existing PSA technology, will ultimately prove to be a useful and accurate test for predicting which men are at risk for a cancer relapse and are most likely to benefit from radiation.
The Screening Paradox? Or Is It Just a Dilemma?
Maybe it’s shabby of me to immediately think: It’s all about money. The pot of gold at the end of the prostate cancer rainbow. Well, the first dip into that pot is billing for all those PSA tests, DREs and biopsies. Standard screening procedures, right? Only it’s not that clear cut. More and more these days, I tend to consult with Dr. Google. Turns out there is disagreement in high places.